Immunohistochemical examination of the tolerance -inducing enzyme indoleamine 2,3 -dioxygenase ( IDO ) in melanoma as a prognostic marker for progression-free- and overall survival

Immunohistochemical examination of the tolerance -inducing enzyme indoleamine 2,3 -dioxygenase ( IDO ) in melanoma as a prognostic marker for progression-free- and overall survival - n/a

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010682

Enrollment

160

Registered

2016-06-30

Start date

2014-11-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43

Interventions

Group 1: 1.Search of all available Histologies from patients with histologic melanoma +/- Sentinel node biopsy with Tumorthickness less than 1mm, more than 1mm or = 4mm

and metastases of melanoma of unknown primary 2.Immunohistochemistry of IDO and other surface antigens of dendritic cells and T cells such as S100, CD68, PD-1, PD L1 of these histologies. 3.Histologic

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: available paraffin sections from patients with melanoma +/- sentinel lymph node with tumor thicknesses of less than 1 mm , greater than or equal 4mm and metastasis of melanoma of unknown primary

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the correlation of the expression of the parameters with the progression-free and overall survival	—

Countries

Germany

Contacts

Public ContactDagmar von Bubnoff

Universitäts-Klinik für Dermatologie undVenerologie,

dagmar.bubnoff@uniklinik-freiburg.de0761-270-67440

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026